Literature DB >> 32422446

Inadequate achievement of ABC goals (HbA1c, blood pressure, LDL-C) among patients with type 2 diabetes in an Iranian population, 2012-2017.

Mehrdad Larry1, Saeid Alizadeh2, Sina Naderi3, Bahareh Salekani4, Mohammad Ali Mansournia5, Soghra Rabizadeh6, Alireza Esteghamati7, Manouchehr Nakhjavani8.   

Abstract

AIMS: This study was designed to evaluate the meeting of ABC goals in patients with type 2 diabetes. The ABC goals were defined as meeting the HbA1c <7%, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg, and LDL-C <100 mg/dL. We also determined the associated factors with meeting the ABC goals, as well as the effectiveness of statin therapy.
METHODS: We designed a cross-sectional study of 2008 type 2 diabetes patients attending the diabetes clinics of Valiasr Hospital of Imam Khomeini Hospital Complex. Meeting ABC goals and their associated factors were analyzed from the registered data.
RESULTS: At the end of the year 2014, 61.3% of patients met the HbA1c goal, which increased to 77.8% in 2017. Blood pressure of 79.5% of patients met the ADA recommendations by the end of the year 2014, reaching 86.6% in 2017. Moreover, 84.5% and 93.8% could reach the LDL-C goal in 2014 and 2017, respectively. The proportion for the patients meeting all three ABC goals were 23.2% and 42.1% in 2014 and 2017, respectively.
CONCLUSIONS: The level of achievement of ABC goals in Iran is lower than expected and it requires a lot of programming effort and follow-up. As patients are followed over the years, controlling ABC becomes much more favorable.
Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABC goals; Blood pressure; HbA1c; LDL-C; Type 2 diabetes

Year:  2020        PMID: 32422446     DOI: 10.1016/j.dsx.2020.05.015

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  1 in total

1.  The Chinese Metabolic Management Centers.

Authors:  Jianmin Liu; Zachary Bloomgarden
Journal:  J Diabetes       Date:  2022-06-17       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.